These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

642 related articles for article (PubMed ID: 27781286)

  • 1. Therapeutic management of inflammatory bowel disease in real-life practice in the current era of anti-TNF agents: analysis of the French administrative health databases 2009-2014.
    Kirchgesner J; Lemaitre M; Rudnichi A; Racine A; Zureik M; Carbonnel F; Dray-Spira R
    Aliment Pharmacol Ther; 2017 Jan; 45(1):37-49. PubMed ID: 27781286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study.
    Murthy SK; Begum J; Benchimol EI; Bernstein CN; Kaplan GG; McCurdy JD; Singh H; Targownik L; Taljaard M
    Gut; 2020 Feb; 69(2):274-282. PubMed ID: 31196874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease.
    Lindsay JO; Armuzzi A; Gisbert JP; Bokemeyer B; Peyrin-Biroulet L; Nguyen GC; Smyth M; Patel H
    Dig Liver Dis; 2017 Oct; 49(10):1086-1091. PubMed ID: 28826571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort.
    Burisch J
    Dan Med J; 2014 Jan; 61(1):B4778. PubMed ID: 24393595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based Study.
    Cheddani H; Dauchet L; Fumery M; Charpentier C; Marie Bouvier A; Dupas JL; Pariente B; Peyrin-Biroulet L; Savoye G; Gower-Rousseau C
    Am J Gastroenterol; 2016 Oct; 111(10):1428-1436. PubMed ID: 27481308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. International variation in medication prescription rates among elderly patients with inflammatory bowel disease.
    Benchimol EI; Cook SF; Erichsen R; Long MD; Bernstein CN; Wong J; Carroll CF; Frøslev T; Sampson T; Kappelman MD
    J Crohns Colitis; 2013 Dec; 7(11):878-89. PubMed ID: 23018106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regional differences in anti-TNF-α therapy and surgery in the treatment of inflammatory bowel disease patients: a Norwegian nationwide cohort study.
    Lirhus SS; Høivik ML; Moum B; Melberg HO
    Scand J Gastroenterol; 2018 Aug; 53(8):952-957. PubMed ID: 30205699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do Thiopurines Reduce the Risk of Surgery in Elderly Onset Inflammatory Bowel Disease? A 20-Year National Population-Based Cohort Study.
    Alexakis C; Saxena S; Chhaya V; Cecil E; Curcin V; Pollok R
    Inflamm Bowel Dis; 2017 Apr; 23(4):672-680. PubMed ID: 28151735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-analysis.
    Billioud V; Ford AC; Tedesco ED; Colombel JF; Roblin X; Peyrin-Biroulet L
    J Crohns Colitis; 2013 Dec; 7(11):853-67. PubMed ID: 23523418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-life efficacy of vedolizumab on endoscopic healing in inflammatory bowel disease - A nationwide Hungarian cohort study.
    Bor R; Fábián A; Matuz M; Szepes Z; Farkas K; Miheller P; Szamosi T; Vincze Á; Rutka M; Szántó K; Bálint A; Nagy F; Milassin Á; Tóth T; Zsigmond F; Bajor J; Müllner K; Lakner L; Papp M; Salamon Á; Horváth G; Sarang K; Schäfer E; Sarlós P; Palatka K; Molnár T
    Expert Opin Biol Ther; 2020 Feb; 20(2):205-213. PubMed ID: 31782939
    [No Abstract]   [Full Text] [Related]  

  • 11. Poor Drug Sustainability in Inflammatory Bowel Disease Patients in Clinical Remission on Thiopurine Monotherapy.
    Balram B; Lubov J; Theoret Y; Afif W; Bitton A; Wild G; Lakatos PL; Bessissow T
    Dig Dis Sci; 2021 May; 66(5):1650-1657. PubMed ID: 32591969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of acute arterial events associated with treatment of inflammatory bowel diseases: nationwide French cohort study.
    Kirchgesner J; Nyboe Andersen N; Carrat F; Jess T; Beaugerie L;
    Gut; 2020 May; 69(5):852-858. PubMed ID: 31446428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Timing of Thiopurine or Anti-TNF Initiation Is Associated with the Risk of Major Abdominal Surgery in Crohn's Disease: A Retrospective Cohort Study.
    González-Lama Y; Suárez C; González-Partida I; Calvo M; Matallana V; de la Revilla J; Magaz M; Bernardo C; Agudo B; Ibarrola P; Relea L; Arévalo J; Vera MI; Abreu L
    J Crohns Colitis; 2016 Jan; 10(1):55-60. PubMed ID: 26520164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of antitumour necrosis factor therapy on surgery in inflammatory bowel disease: a population-based study.
    Hawthorne AB; Arms-Williams B; Cannings-John R; Pollok RCG; Berry A; Harborne P; Trivedi A
    BMJ Open Gastroenterol; 2024 May; 11(1):. PubMed ID: 38777566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Healthcare Utilisation and Drug Treatment in a Large Cohort of Patients with Inflammatory Bowel Disease.
    Cars T; Wettermark B; Löfberg R; Eriksson I; Sundström J; Lördal M
    J Crohns Colitis; 2016 May; 10(5):556-65. PubMed ID: 26733406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in the requirement for early surgery in inflammatory bowel disease in the era of biological agents.
    Guasch M; Cañete F; Ordás I; Iglesias-Flores E; Clos A; Gisbert JP; Taxonera C; Vera I; Mínguez M; Guardiola J; Rivero M; Nos P; Gomollón F; Barrio J; de Francisco R; López-Sanromán A; Martín-Arranz MD; Garcia-Planella E; Camargo R; García-López S; de Castro L; Calvet X; Esteve M; Mañosa M; Domènech E;
    J Gastroenterol Hepatol; 2020 Dec; 35(12):2080-2087. PubMed ID: 32350906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conditions of prescription of anti-TNF agents in newly treated patients with inflammatory bowel disease in France (2011-2013).
    Blotière PO; Rudant J; Barré A; Racine A; Weill A; Peyrin-Biroulet L; Carbonnel F; Alla F
    Dig Liver Dis; 2016 Jun; 48(6):620-5. PubMed ID: 27017107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation.
    Bortlik M; Duricova D; Machkova N; Hruba V; Lukas M; Mitrova K; Romanko I; Bina V; Malickova K; Kolar M; Lukas M
    Scand J Gastroenterol; 2016; 51(2):196-202. PubMed ID: 26329773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term evolution of direct healthcare costs for inflammatory bowel diseases: a population-based study (2006-2015).
    Kim JW; Lee CK; Lee JK; Jeong SJ; Oh SJ; Moon JR; Kim HS; Kim HJ
    Scand J Gastroenterol; 2019 Apr; 54(4):419-426. PubMed ID: 30905222
    [No Abstract]   [Full Text] [Related]  

  • 20. Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study.
    Targownik LE; Benchimol EI; Bernstein CN; Singh H; Lix L; Tennakoon A; Leung S; Aviña A; Coward S; Jones J; Kaplan G; Murthy SK; Nguyen GC; Peña-Sánchez JN
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1788-1798.e2. PubMed ID: 30448599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.